GSK Q1 beats estimates
GSK
1,352.00p
15:40 14/11/24
-0.73%
-10.00p
GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
FTSE 100
8,067.42
15:40 14/11/24
n/a
n/a
FTSE 350
4,456.43
15:40 14/11/24
n/a
n/a
FTSE All-Share
4,414.10
15:40 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,710.58
15:40 14/11/24
0.53%
103.57
The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.
Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.
Reporting by Frank Prenesti for Sharecast.com